Late post-COVID syndrome: clinical complications beyong 12 weeks

Shynar S. Nurusheva 1 * , Saule T. Abisheva 1, Anilim B. Abisheva 1, Kristina S. Rutskaya-Moroshan 1, Serik A. Shaimerdenov 2
More Detail
1 NJSC «Astana Medical University», Department of Family Medicine №1, Astana, Republic of Kazakhstan
2 City polyclinic №4, Astana, Republic of Kazakhstan
* Corresponding Author
J CLIN MED KAZ, Volume 21, Issue 1, pp. 9-13. https://doi.org/10.23950/jcmk/14268
OPEN ACCESS 336 Views 252 Downloads
Download Full Text (PDF)

ABSTRACT

The persistent and diverse manifestations of post-COVID syndrome present a significant challenge for global healthcare. Beyond the acute phase of infection, individuals continue to grapple with lingering symptoms affecting various organ systems, including the respiratory, cardiovascular, neurological, and endocrine systems. In the respiratory realm, symptoms such as cough, dyspnea, and fatigue endure, particularly in those with a history of severe COVID-19. The cardiovascular impact manifests as chest pain, arrhythmias, and heightened risks of thromboembolic events, emphasizing the intricate connection between COVID-19 and cardiovascular complications. Neurological complications, ranging from headaches to more severe disorders, further contribute to the complex sequelae of post-COVID syndrome. Additionally, disruptions in the endocrine system, including new-onset diabetes and thyroid abnormalities, pose long-term challenges for affected individuals. The review discusses the clinical management challenges posed by the multifaceted nature of post-COVID complications and the necessity for tailored multidisciplinary approaches. A holistic and compassionate response to the long-term effects of COVID-19 requires collaboration across healthcare professionals, researchers and the broader community. By navigating these challenges collectively, we can pave the way for a more comprehensive and effective approach to post-COVID care.

CITATION

Nurusheva SS, Abisheva ST, Abisheva AB, Rutskaya-Moroshan KS, Shaimerdenov SA. Late post-COVID syndrome: clinical complications beyong 12 weeks. J CLIN MED KAZ. 2024;21(1):9-13. https://doi.org/10.23950/jcmk/14268

REFERENCES

  • Fernández-de-Las-Peñas C. One year later: Prevalence of long-COVID symptoms. European Journal of Internal Medicine. 2023; 115: 37-8. https://doi.org/10.1016/j.ejim.2023.07.001.
  • Welte T. Post-COVID syndrome-more questions than answers. Deutsches Ärzteblatt International. 2022; 119(10): 165. https://doi.org/10.3238/arztebl.m2022.0154.
  • Soriano JB, Murthy S, Marshall JC, Relan P, Diaz JV. A clinical case definition of post-COVID-19 condition by a Delphi consensus. The Lancet Infectious Diseases. 2022; 22(4): e102-e7. https://doi.org/10.1016/S1473-3099(21)00703-9.
  • Fernández-de-Las-Peñas C, Palacios-Ceña D, Gómez-Mayordomo V, Florencio LL, Cuadrado ML, Plaza-Manzano G, et al. Prevalence of post-COVID-19 symptoms in hospitalized and non-hospitalized COVID-19 survivors: A systematic review and meta-analysis. European journal of internal medicine. 2021; 92: 55-70. https://doi.org/10.1016/j.ejim.2021.06.009.
  • Esendağli D, Yilmaz A, AkÇAy MŞ, Özlü T. Post-COVID syndrome: pulmonary complications. Turkish journal of medical sciences. 2021; 51(7): 3359-71. https://doi.org/10.3906/sag-2106-238.
  • Leask A. COVID-19: is fibrosis the killer? Journal of Cell Communication and Signaling. 2020; 14: 255. https://doi.org/10.1007/s12079-020-00569-0.
  • Arnold DT, Hamilton FW, Milne A, Morley AJ, Viner J, Attwood M, et al. Patient outcomes after hospitalisation with COVID-19 and implications for follow-up: results from a prospective UK cohort. Thorax. 2021; 76(4): 399-401. https://doi.org/10.1136/thoraxjnl-2020-216086.
  • Goërtz YMJ, Van Herck M, Delbressine JM, Vaes AW, Meys R, Machado FVC, et al. Persistent symptoms 3 months after a SARSCoV-2 infection: the post-COVID-19 syndrome? ERJ open research. 2020; 6(4). https://doi.org/10.1183/23120541.00542-2020.
  • Jacobson KB, Rao M, Bonilla H, Subramanian A, Hack I, Madrigal M, et al. Patients with uncomplicated coronavirus disease 2019 (COVID-19) have long-term persistent symptoms and functional impairment similar to patients with severe COVID-19: a cautionary tale during a global pandemic. Clinical Infectious Diseases. 2021; 73(3): e826-e9. https://doi.org/10.1093/cid/ciab103.
  • Sykes DL, Holdsworth L, Jawad N, Gunasekera P, Morice AH, Crooks MG. Post-COVID-19 symptom burden: what is long-COVID and how should we manage it? Lung. 2021; 199: 113-9. https://doi.org/10.1007/s00408-021-00423-z.
  • Shi S, Qin M, Cai Y, Liu T, Shen B, Yang F, et al. Characteristics and clinical significance of myocardial injury in patients with severe coronavirus disease 2019. European heart journal. 2020; 41(22): 2070-9. https://doi.org/10.1093/eurheartj/ehaa408.
  • Shah W, Hillman T, Playford ED, Hishmeh L. Managing the long term effects of covid-19: summary of NICE, SIGN, and RCGP rapid guideline. BMJ. 2021; 372. https://doi.org/10.1136/bmj.n136.
  • Visco V, Vitale C, Rispoli A, Izzo C, Virtuoso N, Ferruzzi GJ, et al. Post-COVID-19 syndrome: involvement and interactions between respiratory, cardiovascular and nervous systems. Journal of clinical medicine. 2022; 11(3): 524. https://doi.org/10.3390/jcm11030524.
  • Liang L, Yang B, Jiang N, Fu W, He X, Zhou Y, et al. Three-month follow-up study of survivors of coronavirus disease 2019 after discharge. Journal of Korean medical science. 2020; 35(47). https://doi.org/10.3346/jkms.2020.35.e418.
  • Shrestha AB, Mehta A, Pokharel P, Mishra A, Adhikari L, Shrestha S, et al. Long COVID syndrome and cardiovascular manifestations: a systematic review and meta-analysis. Diagnostics. 2023; 13(3): 491. https://doi.org/10.3390/diagnostics13030491.
  • 16. Xiong Q, Xu M, Li J, Liu Y, Zhang J, Xu Y, et al. Clinical sequelae of COVID-19 survivors in Wuhan, China: a single-centre longitudinal study. Clinical microbiology and infection. 2021; 27(1): 89-95. https://doi.org/10.1016/j.cmi.2020.09.023.
  • South AM, Diz DI, Chappell MC. COVID-19, ACE2, and the cardiovascular consequences. American Journal of Physiology-Heart and Circulatory Physiology. 2020. https://doi.org/10.1152/ajpheart.00217.2020.
  • Premraj L, Kannapadi NV, Briggs J, Seal SM, Battaglini D, Fanning J, et al. Mid and long-term neurological and neuropsychiatric manifestations of post-COVID-19 syndrome: A meta-analysis. Journal of the neurological sciences. 2022; 434: 120162. https://doi.org/10.1016/j.jns.2022.120162.
  • Rass V, Beer R, Schiefecker AJ, Kofler M, Lindner A, Mahlknecht P, et al. Neurological outcome and quality of life 3 months after COVID-19: A prospective observational cohort study. European journal of neurology. 2021; 28(10): 3348-59. https://doi.org/10.1111/ene.14803.
  • Taquet M, Geddes JR, Husain M, Luciano S, Harrison PJ. 6-month neurological and psychiatric outcomes in 236 379 survivors of COVID-19: a retrospective cohort study using electronic health records. The Lancet Psychiatry. 2021; 8(5): 416-27. https://doi.org/10.1016/S2215-0366(21)00084-5.
  • Okrzeja J, Garkowski A, Kubas B, Moniuszko-Malinowska A. Imaging and neuropathological findings in patients with Post COVID-19 Neurological Syndrome – A review. Frontiers in Neurology. 2023; 14: 1136348. https://doi.org/10.3389/fneur.2023.1136348.
  • Pal R, Banerjee M. COVID-19 and the endocrine system: exploring the unexplored. Journal of endocrinological investigation. 2020; 43: 1027-31. https://doi.org/10.1007/s40618-020-01276-8.
  • Popescu M, Ghemigian A, Vasile CM, Costache A, Carsote M, Ghenea AE. The new entity of subacute thyroiditis amid the COVID-19 pandemic: from infection to vaccine. Diagnostics. 2022; 12(4): 960. https://doi.org/10.3390/diagnostics12040960.
  • Ilera V, Delfino LC, Zunino A, Glikman P, Drnovsek M, Reyes A, et al. Correlation between inflammatory parameters and pituitarythyroid axis in patients with COVID-19. Endocrine. 2021; 74: 455-60. https://doi.org/10.1007/s12020-021-02863-2.
  • Finsterer J, Scorza FA. The pituitary gland in SARS-CoV-2 infections, vaccinations, and post-COVID syndrome. Clinics. 2023; 78. https://doi.org/10.1016/j.clinsp.2022.100157.
  • Geslot A, Chanson P, Caron P, editors. Covid-19, the thyroid and the pituitary – The real state of play 2022: Elsevier. https://doi.org/10.1016/j.ando.2021.12.004.
  • Kanczkowski W, Gaba WH, Krone N, Varga Z, Beuschlein F, Hantel C, et al. Adrenal gland function and dysfunction during COVID-19. Hormone and Metabolic Research. 2022; 54(08): 532-9. https://doi.org/10.1055/a-1873-2150.
  • Moreno-Perez O, Merino E, Alfayate R, Torregrosa ME, Andres M, Leon-Ramirez JM, et al. Male pituitary-gonadal axis dysfunction in post-acute COVID-19 syndrome-Prevalence and associated factors: A Mediterranean case series. Clinical Endocrinology. 2022; 96(3): 353-62. https://doi.org/10.1111/cen.14537.
  • Shrestha DB, Budhathoki P, Raut S, Adhikari S, Ghimire P, Thapaliya S, et al. New-onset diabetes in COVID-19 and clinical outcomes: A systematic review and meta-analysis. World Journal of Virology. 2021; 10(5): 275. https://doi.org/10.5501/wjv.v10.i5.275.
  • Keerthi BY, Sushmita G, Khan EA, Thomas V, Cheryala V, Shah C, et al. New onset diabetes mellitus in post-COVID-19 patients. Journal of family medicine and primary care. 2022; 11(10): 5961. https://doi.org/10.4103/jfmpc.jfmpc_316_22.
  • Bode B, Garrett V, Messler J, McFarland R, Crowe J, Booth R, et al. Glycemic characteristics and clinical outcomes of COVID-19 patients hospitalized in the United States. Journal of diabetes science and technology. 2020; 14(4): 813-21. https://doi.org/10.1177/1932296820924469.
  • Dambal A, Nekkanti A, Yashika C. The incidence, risk factors, and outcome of new-onset diabetes among post-COVID-19 patients: A single-center study. Asian Journal of Medical Sciences. 2023; 14(3). https://doi.org/10.3126/ajms.v14i3.51510.
  • Li H, Tian S, Chen T, Cui Z, Shi N, Zhong X, et al. Newly diagnosed diabetes is associated with a higher risk of mortality than known diabetes in hospitalized patients with COVID-19. Diabetes, obesity and metabolism. 2020; 22(10): 1897-906. https://doi.org/10.1111/dom.14099.